Says addressing “inconsistent” U.S. performance. Believes company can deliver mid-single digit revenue with EPS growing faster than revenue. Notes that the company moved from legacy ERP platform in July to SAP, says “things worked well at first,” identified it didn’t work as expected, which will create some challenges in revenue in 2H24. Zimmer Biomet says situation is well managed, and it understands the root cause, but that it will impact 2H24 revenue. Says impact could be about 1% to FY24 sales. Comments taken from the Wells Fargo Healthcare Conference. Shares of Zimmer Biomet are down 7.5% in early trading to $105.87.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Evercore estimates 15c EPS impact from Zimmer Biomet sales warning
- Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2024
- Zimmer Biomet price target lowered to $120 from $130 at Canaccord
- Zimmer Biomet price target lowered to $128 from $138 at Raymond James
- Zimmer Biomet price target lowered to $115 from $140 at Deutsche Bank